Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Epizyme Inc. buy stratec

Start price
€9.70
24.09.18 / 50%
Target price
€23.45
04.11.21
Performance (%)
-55.86%
End price
€4.28
05.11.21
Summary
This prediction ended on 05.11.21 with a price of €4.28. Massive losses of -55.86% were the result for the BUY prediction by stratec. stratec has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Epizyme Inc. - - - -
iShares Core DAX® 2.149% 5.415% 21.385% 22.595%
iShares Nasdaq 100 0.838% 1.926% 44.386% 55.330%
iShares Nikkei 225® 1.143% 2.887% 27.641% 9.481%
iShares S&P 500 1.265% 3.698% 33.327% 49.646%

Comments by stratec for this prediction

In the thread Epizyme Inc. diskutieren
Prediction Buy
Perf. (%) -55.86%
Target price 23.452
Change
Ends at 04.11.21

stratec stimmt dem Sentiment von 'Buy' zu



Oppenheimer's call:


An annoncement of the partial clinical hold being lifted by FDA supports our outlook for tazemetostat. Tazemetostat is currently being studied in clinical programs in INI-1 negative tumors, synovial sarcomas, follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), and mesothelioma. While the partial clinical hold may have delayed enrollment in some studies, these are not currently factored into our outlook; therefore, the hold had little impact on our outlook. The news removes a regulatory overhang and supports our outlook for Epizyme.”




In the thread Trading Epizyme Inc.
Prediction Buy
Perf. (%) -55.86%
Target price 23.452
Change
Ends at 04.11.21

Die von stratec gewählte maximale Laufzeit wurde überschritten